Shares of GTx, Inc. (NASDAQ:GTXI) have earned a consensus broker rating score of 3.00 (Hold) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold rating.
Brokers have set a twelve-month consensus target price of $1.75 for the company, according to Zacks. Zacks has also assigned GTX an industry rank of 55 out of 255 based on the ratings given to related companies.
Separately, ValuEngine raised GTX from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd.
GTXI stock traded down $0.04 during mid-day trading on Monday, hitting $1.18. The stock had a trading volume of 101,603 shares, compared to its average volume of 283,451. GTX has a 1-year low of $0.74 and a 1-year high of $25.60. The firm has a market cap of $28.38 million, a P/E ratio of -0.67 and a beta of 2.60.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE increased its holdings in shares of GTX by 2,491.6% during the 4th quarter. Bank of America Corp DE now owns 205,046 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 197,134 shares during the last quarter. Two Sigma Advisers LP acquired a new position in shares of GTX during the 4th quarter valued at about $36,000. Two Sigma Investments LP increased its holdings in shares of GTX by 25.9% during the 4th quarter. Two Sigma Investments LP now owns 131,323 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 26,983 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of GTX during the 4th quarter valued at about $85,000. Finally, Virtu Financial LLC acquired a new position in shares of GTX during the 4th quarter valued at about $52,000. 13.24% of the stock is currently owned by institutional investors and hedge funds.
GTX Company Profile
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?
Get a free copy of the Zacks research report on GTX (GTXI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.